ANAGRELIDE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Anagrelide Hydrochloride, and when can generic versions of Anagrelide Hydrochloride launch?
Anagrelide Hydrochloride is a drug marketed by Barr, Chartwell Rx, Impax Labs, Ivax Sub Teva Pharms, Natco Pharma Usa, Rising, Roxane, Torrent, and Watson Labs. and is included in nine NDAs.
The generic ingredient in ANAGRELIDE HYDROCHLORIDE is anagrelide hydrochloride. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the anagrelide hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Anagrelide Hydrochloride
A generic version of ANAGRELIDE HYDROCHLORIDE was approved as anagrelide hydrochloride by IMPAX LABS on April 18th, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ANAGRELIDE HYDROCHLORIDE?
- What are the global sales for ANAGRELIDE HYDROCHLORIDE?
- What is Average Wholesale Price for ANAGRELIDE HYDROCHLORIDE?
Summary for ANAGRELIDE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 9 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Clinical Trials: | 24 |
| Patent Applications: | 749 |
| DailyMed Link: | ANAGRELIDE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for ANAGRELIDE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Merck Sharp & Dohme LLC | Phase 3 |
| Celgene | Phase 3 |
| EPS International | Phase 3 |
Pharmacology for ANAGRELIDE HYDROCHLORIDE
| Drug Class | Platelet-reducing Agent |
| Mechanism of Action | Phosphodiesterase 3 Inhibitors |
| Physiological Effect | Decreased Platelet Production |
Anatomical Therapeutic Chemical (ATC) Classes for ANAGRELIDE HYDROCHLORIDE
US Patents and Regulatory Information for ANAGRELIDE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Barr | ANAGRELIDE HYDROCHLORIDE | anagrelide hydrochloride | CAPSULE;ORAL | 076530-001 | Apr 18, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs | ANAGRELIDE HYDROCHLORIDE | anagrelide hydrochloride | CAPSULE;ORAL | 076417-002 | Apr 18, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ivax Sub Teva Pharms | ANAGRELIDE HYDROCHLORIDE | anagrelide hydrochloride | CAPSULE;ORAL | 076468-001 | Apr 18, 2005 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
